Allemani Claudia, Sant Milena, De Angelis Roberta, Marcos-Gragera Rafael, Coebergh Jan Willem
Epidemiology Unit, Department of Preventive and Predictive Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
Cancer. 2006 Jul 15;107(2):352-60. doi: 10.1002/cncr.21995.
The survival of patients with Hodgkin disease (HD) varies markedly across Europe and generally is shorter than the survival of patients in the U.S. To investigate these differences, the authors compared population-based HD survival in relation to morphologic type among populations in Europe and the U.S.
The authors analyzed 6726 patients from 37 cancer registries that participated in EUROCARE-3 and 3442 patients from 9 U.S. Surveillance, Epidemiology, and End Results (SEER) registries. Patients were diagnosed during 1990 to 1994 and were followed for at least 5 years. The European registries were grouped into EUROCARE West, EUROCARE UK, and EUROCARE East. Morphologic groups were nodular sclerosis, mixed cellularity, lymphocyte depletion, lymphocyte predominance, and not otherwise specified (NOS). The influence of morphology on geographic differences in 5-year relative survival was explored by using multiple regression analysis.
In the model that was adjusted by age, gender, and years since diagnosis, the relative excess risk (RER) of death was 0.93 (95% confidence interval [95% CI], 0.81-1.05) in EUROCARE West, 1.15 (95% CI, 1.04-1.28) in EUROCARE UK, and 1.39 (95% CI, 1.21-1.60) in EUROCARE East (compared with the SEER data). When morphology was included, EUROCARE UK and SEER no longer differed (RER, 1.06; 95% CI, 0.95-1.18). Morphology distribution varied markedly across Europe and much less in the U.S., with nodular sclerosis less common in Europe (45.9%) than the U.S. (61.7%). The RER data showed that patients who had lymphocyte depletion, NOS, and mixed cellularity had a significantly worse prognoses compared with patients who had nodular sclerosis, whereas patients who had lymphocyte predominance had the best prognosis.
The current results provide population-based evidence that morphology strongly influences the prognosis of patients with HD. However differences in the morphologic case mix explains only some of the geographic variations observed in survival.
霍奇金淋巴瘤(HD)患者的生存率在欧洲各地差异显著,总体上低于美国患者的生存率。为了研究这些差异,作者比较了欧洲和美国人群中基于形态学类型的HD生存率。
作者分析了来自参与EUROCARE-3的37个癌症登记处的6726例患者以及来自美国9个监测、流行病学和最终结果(SEER)登记处的3442例患者。患者于1990年至1994年期间被诊断,并随访至少5年。欧洲登记处分为EUROCARE西部、EUROCARE英国和EUROCARE东部。形态学分组为结节硬化型、混合细胞型、淋巴细胞消减型、淋巴细胞为主型以及未另行说明(NOS)型。通过多元回归分析探讨形态学对5年相对生存率地理差异的影响。
在根据年龄、性别和诊断后年限进行调整的模型中,EUROCARE西部的死亡相对超额风险(RER)为0.93(95%置信区间[95%CI],0.81 - 1.05),EUROCARE英国为1.15(95%CI,1.04 - 1.28),EUROCARE东部为1.39(95%CI,1.21 - 1.60)(与SEER数据相比)。纳入形态学因素后,EUROCARE英国和SEER的数据不再有差异(RER,1.06;95%CI,0.95 - 1.18)。形态学分布在欧洲各地差异显著,在美国则小得多,结节硬化型在欧洲(45.9%)比在美国(61.7%)少见。RER数据显示,与结节硬化型患者相比,淋巴细胞消减型、NOS型和混合细胞型患者的预后明显更差,而淋巴细胞为主型患者的预后最佳。
目前的结果提供了基于人群的证据,表明形态学对HD患者的预后有强烈影响。然而,形态学病例组合的差异仅解释了观察到的生存地理差异的一部分。